Camurus AB, a pioneering biopharmaceutical company headquartered in Sweden, focuses on developing innovative medicines for patients with severe and chronic conditions. Founded in 2016, Camurus has rapidly established itself in the pharmaceutical industry, particularly in the fields of pain management and addiction treatment. The company is renowned for its proprietary FluidCrystal® technology, which enables the formulation of long-acting injectable therapies. This unique approach enhances patient compliance and treatment outcomes. Camurus has achieved significant milestones, including the successful launch of its lead product, Buvidal®, for opioid dependence, positioning itself as a leader in the market. With a strong presence in Europe and expanding operations globally, Camurus continues to make strides in improving patient care through its advanced therapeutic solutions.
How does Camurus's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Camurus's score of 46 is higher than 64% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2023, Camurus, headquartered in Sweden (SE), reported total carbon emissions of approximately 5,618,000 kg CO2e. This figure includes Scope 1 emissions of about 1,589,000 kg CO2e, Scope 2 emissions of approximately 1,748,000 kg CO2e, and Scope 3 emissions totalling around 3,856,000 kg CO2e. Notably, the company has set ambitious greenhouse gas reduction targets, aiming for a 55% reduction by 2030 from a 2019 baseline across all scopes. Additionally, Camurus is committed to achieving carbon neutrality by 2040, specifically targeting a 35% reduction in Scope 1 emissions by 2025. These initiatives reflect the company's dedication to addressing climate change and reducing its environmental impact.
Access structured emissions data, company-specific emission factors, and source documents
| 2022 | 2023 | |
|---|---|---|
| Scope 1 | 162,400 | 0,000,000 |
| Scope 2 | 8,990 | 00,000 |
| Scope 3 | 60,300 | 0,000,000 |
Camurus's Scope 3 emissions, which increased significantly last year and increased significantly since 2022, demonstrating supply chain emissions tracking. Most of their carbon footprint comes from suppliers and value chain emissions, with Scope 3 emissions accounting for 71% of total emissions under the GHG Protocol, with "Downstream Transportation & Distribution" being the largest emissions source at 7% of Scope 3 emissions.
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Camurus has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
